New drug developed to treat Fabry's disease

October 15, 2003

New York-Treatment is now available for Fabry's disease, a lysosomal storage disorder with ophthalmologic findings. In April, the FDA granted Orphan Drug designation for agalsidase beta (Fabrazyme, Genzyme General), an enzyme replacement therapy, for the treatment of this progressive and potentially fatal disease.